This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 116/14/1577    most recent CIRCULATIONAHA.107.689810v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, Q. Articles by Bolli, R. Search for Related Content PubMed PubMed Citation Articles by Li, Q. Articles by Bolli, R. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Medline Plus Health Information Genes and Gene Therapy Heart Attack Related Collections Animal models of human disease Ischemic biology - basic studies Gene therapy

(Circulation. 2007;116:1577-1584.)
© 2007 American Heart Association, Inc.

Molecular Cardiology

Cardioprotection Afforded by Inducible Nitric Oxide Synthase Gene Therapy Is Mediated by Cyclooxygenase-2 via a Nuclear Factor-B–Dependent Pathway

Qianhong Li, MD, PhD; Yiru Guo, MD; Wei Tan, MD; Qinghui Ou, MD; Wen-Jian Wu, MSc; Diana Sturza, MD; Buddhadeb Dawn, MD; Greg Hunt, BS; Chuanjue Cui, MD; Roberto Bolli, MD

From the Institute of Molecular Cardiology, University of Louisville, Louisville, Ky.

Correspondence to Roberto Bolli, MD, Division of Cardiology, University of Louisville, Louisville, KY 40292. E-mail rbolli{at}louisville.edu

Received January 12, 2007; accepted July 31, 2007.

Background— Gene therapy with inducible nitric oxide synthase (iNOS) markedly reduces myocardial infarct size; this effect is associated with cyclooxygenase-2 (COX-2) upregulation and is ablated by COX-2 inhibitors. However, pharmacological inhibitors are limited by relative lack of specificity; furthermore, the mechanism whereby iNOS gene therapy upregulates COX-2 remains unknown. Accordingly, we used genetically engineered mice to test the hypothesis that the cardioprotection afforded by iNOS gene transfer is mediated by COX-2 upregulation via a nuclear factor (NF)-B–dependent pathway.

Methods and Results— Mice received an intramyocardial injection of Av3/LacZ (LacZ group) or Av3/iNOS (iNOS group); 3 days later, myocardial infarction was produced by a 30-minute coronary occlusion followed by 4 hours of reperfusion. Among Av3/LacZ-treated mice, infarct size was similar in COX-2^–/– and wild-type groups. iNOS gene transfer (confirmed by iNOS immunoblotting and activity assays) markedly reduced infarct size in wild-type mice but failed to do so in COX-2^–/– mice. In transgenic mice with cardiac-specific expression of a dominant-negative mutant of IB (IB^S32A,S36A), the upregulation of phosphorylated IB, activation of NF-B, and cardiac COX-2 protein expression 3 days after iNOS gene therapy were abrogated, which was associated with the abolishment of the cardioprotective effects afforded by iNOS gene therapy.

Conclusions— These data provide strong genetic evidence that COX-2 is an obligatory downstream effector of iNOS-dependent cardioprotection and that NF-B is a critical link between iNOS and COX-2. Thus, iNOS imparts its protective effects, at least in part, by recruiting NF-B, leading to COX-2 upregulation. However, COX-2 does not play an important cardioprotective role under basal conditions (when iNOS is not upregulated).

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				Q. Li, Y. Guo, Q. Ou, C. Cui, W.-J. Wu, W. Tan, X. Zhu, L. B. Lanceta, S. K. Sanganalmath, B. Dawn, et al. Gene Transfer of Inducible Nitric Oxide Synthase Affords Cardioprotection by Upregulating Heme Oxygenase-1 Via a Nuclear Factor-{kappa}B-Dependent Pathway Circulation, September 29, 2009; 120(13): 1222 - 1230. [Abstract] [Full Text] [PDF]

				C.-C. Lin, W.-N. Lin, W.-J. Wang, C.-C. Sun, W.-H. Tung, H.-H. Wang, and C.-M. Yang Functional coupling expression of COX-2 and cPLA2 induced by ATP in rat vascular smooth muscle cells: role of ERK1/2, p38 MAPK, and NF-{kappa}B Cardiovasc Res, June 1, 2009; 82(3): 522 - 531. [Abstract] [Full Text] [PDF]

				Y. Sun, O. A. Carretero, J. Xu, N.-E. Rhaleb, J. J. Yang, P. J. Pagano, and X.-P. Yang Deletion of Inducible Nitric Oxide Synthase Provides Cardioprotection in Mice With 2-Kidney, 1-Clip Hypertension Hypertension, January 1, 2009; 53(1): 49 - 56. [Abstract] [Full Text] [PDF]